Literature DB >> 16946218

Misoprostol administered by epithelial routes: Drug absorption and uterine response.

Karen R Meckstroth1, Amy K Whitaker, Suzanne Bertisch, Alisa B Goldberg, Philip D Darney.   

Abstract

OBJECTIVE: To quantify and compare serum levels and uterine effects following vaginal (dry), vaginal (moistened), buccal, and rectal misoprostol administration.
METHODS: Forty women seeking elective abortion between 6 and 12 6/7 weeks were randomly assigned to receive 400 mug of misoprostol by one of four routes. A 2.5-mm pressure monitoring catheter was placed through the cervix to the uterine fundus to record uterine tone and activity during the 5-hour observation period. Serum levels of misoprostol acid were measured at 15 and 30 minutes, then every 30 minutes.
RESULTS: The four groups were similar in age, race or ethnicity, body mass index, parity, and gestation. Serum levels after vaginal, vaginal moistened and buccal administration rose gradually, peaked between 15 and 120 minutes and fell slowly. Vaginal and vaginal moistened routes produced higher peak serum levels than buccal and rectal (445.9 and 427.1 compared with 264.8 and 202.2 pg/mL; P = .03) and higher serum concentration area under the curve at 5 hours (1,025.0 and 1279.4 compared with 519.6 and 312.5 pg-hr/mL; P < .001). Uterine tone and activity, however, were similar for buccal and the two vaginal routes. After rectal administration, serum levels peaked earlier (P < .001) then dropped more abruptly, and peak uterine tone (P < .001) and total activity (P = .04) were lower than after the other routes.
CONCLUSION: Although serum levels were lower for buccal compared with the vaginal routes, the three routes produced similar uterine tone and activity. Rectal administration produced lower uterine tone and activity. Vaginal serum levels were two to three and a half times higher than those observed in prior misoprostol pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946218     DOI: 10.1097/01.AOG.0000230398.32794.9d

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  12 in total

1.  Management of first trimester pregnancy loss can be safely moved into the office.

Authors:  Jana L Allison; Rebecca S Sherwood; Danny J Schust
Journal:  Rev Obstet Gynecol       Date:  2011

2.  Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss.

Authors:  Courtney A Schreiber; Mitchell D Creinin; Jessica Atrio; Sarita Sonalkar; Sarah J Ratcliffe; Kurt T Barnhart
Journal:  N Engl J Med       Date:  2018-06-07       Impact factor: 91.245

3.  Uses of misoprostol in obstetrics and gynecology.

Authors:  Rebecca Allen; Barbara M O'Brien
Journal:  Rev Obstet Gynecol       Date:  2009

4.  The methodology for developing a prospective meta-analysis in the family planning community.

Authors:  David K Turok; Eve Espey; Alison B Edelman; Pamela S Lotke; Eva H Lathrop; Stephanie B Teal; Janet C Jacobson; Sara E Simonsen; Kenneth F Schulz
Journal:  Trials       Date:  2011-04-29       Impact factor: 2.279

5.  Acceptability and safety profile of oral and sublingual misoprostol for uterine evacuation following early fetal demise.

Authors:  Devendra Singh Kushwah; Beenu Kushwah; Mohd Tariq Salman; V K Verma
Journal:  Indian J Pharmacol       Date:  2011-05       Impact factor: 1.200

Review 6.  Adjunctive Agents for Cervical Preparation in Second Trimester Surgical Abortion.

Authors:  Jessika A Ralph; Lee P Shulman
Journal:  Adv Ther       Date:  2019-04-19       Impact factor: 3.845

7.  A randomized controlled trial of misoprostol and sulprostone to end pregnancy after fetal death.

Authors:  Kristin Van Mensel; Filip Claerhout; Patrick Debois; Marc J N C Keirse; Myriam Hanssens
Journal:  Obstet Gynecol Int       Date:  2009-09-06

Review 8.  Management of pain associated with the insertion of intrauterine contraceptives.

Authors:  K Gemzell-Danielsson; D Mansour; C Fiala; A M Kaunitz; L Bahamondes
Journal:  Hum Reprod Update       Date:  2013-05-12       Impact factor: 15.610

9.  Comparison of two doses and two routes of administration of misoprostol after pre-treatment with mifepristone for early pregnancy termination.

Authors:  Helena von Hertzen; Gilda Piaggio; Lena Marions
Journal:  Reprod Health       Date:  2008-06-23       Impact factor: 3.223

Review 10.  Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis.

Authors:  Katherine Whitehouse; Ashley Brant; Marita Sporstol Fonhus; Antonella Lavelanet; Bela Ganatra
Journal:  Contracept X       Date:  2020-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.